MacroGenics, Inc. (MGNX)
| Market Cap | 1.21B |
| Revenue (ttm) | 118.58M |
| Net Income (ttm) | -129.34M |
| Shares Out | 60.07M |
| EPS (ttm) | -2.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 345,147 |
| Open | 20.51 |
| Previous Close | 20.54 |
| Day's Range | 19.72 - 20.87 |
| 52-Week Range | 18.16 - 36.48 |
| Beta | 2.20 |
| Analysts | Buy |
| Price Target | 36.25 (+83.6%) |
| Est. Earnings Date | Nov 4, 2021 |
About MGNX
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, w...
Financial Performance
In 2020, MacroGenics's revenue was $104.88 million, an increase of 63.40% compared to the previous year's $64.19 million. Losses were -$129.74 million, -14.54% less than in 2019.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for MacroGenics stock is "Buy." The 12-month stock price forecast is 36.25, which is an increase of 83.64% from the latest price.
News
MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation
MacroGenics Inc (NASDAQ: MGNX) announced preliminary safety and anti-tumor activity data from dose-expansion cohorts of the Phase 1 trial of MGC018. The data was presented at the 2021 European Society f...
Why MacroGenics Stock Is Tanking Today
Investors weren't thrilled with the company's latest clinical data.
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presente...
ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combinatio...
ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?
MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i...
Why MacroGenics Soared Nearly 9% Higher Today
Investors are signaling hope in the company's top drug, despite a disappointing final analysis.
MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis
MacroGenics Inc (NASDAQ: MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a head-to-head matchup with breast cancer med Herceptin. But Margenza's over...
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Me...
ROCKVILLE, MD, Sept. 07, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Sept. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
Why MacroGenics Stock Is Tumbling Today
The company provided its Q2 update.
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -135.71% and -13.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
ROCKVILLE, Md., July 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
MacroGenics (MGNX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeuti...
Hot Small-Cap Stocks To Watch With Potential Cancer Breakthroughs
Could new cancer treatment breakthroughs be a bullish sign for small cap stocks?
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advised to c...
MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal
MacroGenics Inc (NASDAQ: MGNX) and Zai Lab Limited (NASDAQ: ZLAB) have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules. The first collaborati...
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific ...
ROCKVILLE, MD, SHANGHAI and SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal-ant...
Why MacroGenics Stock Is Tumbling Today
The company announced preliminary phase 1 results for its tumor-fighting drug MGC018.
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics ...
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -69.81% and -45.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results
ROCKVILLE, Md., April 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeuti...
Will MacroGenics (MGNX) Report Negative Earnings Next Week? What You Should Know
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.